Subscribe to our newsletter.
Instructions for Use
For any missing information or if you require additional details, please do not hesitate to contact us.
Personalized medicine is becoming increasingly important in cancer therapy. One genetic feature that can significantly influence the efficacy of antibody-based therapies is the Fc gamma receptor (FCGR) gene. The FCGR StripAssay® identifies specific variants of this gene—namely FCGR2A-H131R and FCGR3A-F158V—providing a crucial tool for potentially optimizing cancer treatment strategies.
Studies have shown that individuals carrying higher-affinity alleles, such as FCGR2A-131His (rs1801274) or FCGR3A-158Val (rs396991), show enhanced responses to monoclonal antibody therapies. In the context of colorectal cancer, 56% of patients with the FCGR3A-158 F/F genotype responded positively to treatments with cetuximab and bevacizumab. This number dropped significantly for patients with the heterozygous F/V and homozygous V/V genotypes, to 25% and 8%, respectively. Similarly, breast cancer patients with the genotypes FCGR2A-131 H/H and FCGR3A-158V/V showed favorable responses to trastuzumab therapy.
The FCGR StripAssay® employs a three-step methodology that includes DNA isolation, PCR amplification using biotinylated primers, and hybridization of the amplification products to a test strip containing allele-specific oligonucleotide probes. The procedure is intended for research use only and focuses on detecting two polymorphic loci: FCGRIIA H131R and FCGRIIIA F158V.
The FCGR StripAssay® holds significant promise for the field of personalized cancer therapy. While additional research is needed to make FCGR genotyping a standard part of clinical decision-making, the potential benefits—particularly in optimizing antibody-based therapies—are undeniable. This assay could play a pivotal role in delivering more effective, personalized treatment plans for cancer patients.